Drug Resistance to HIV-1 Integrase Inhibitors among Treatment-naive Patients in Jiangsu,China |
| |
| Authors: | YIN Yue Qi LU Jing ZHOU Ying SHI Ling En YUAN De Fu CHEN Jian Shuang XUAN Yan HU Hai Yang ZHANG Zhi XU Xiao Qin FU Geng Feng WANG Bei |
| |
| Institution: | 1. Department of Epidemiology and Health Statistics, Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, Jiangsu, China;2. Department of HIV/STD Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, Jiangsu, China |
| |
| Abstract: | Integrase strand transfer inhibitors (InSTIs) have been widely used in recent years because of their high genetic barrier to resistance. The World Health Organization (WHO) has recommended dolutegravir (DTG)-containing regimens as the preferred first- and second-line antiretroviral therapy (ART) regimens for people living with human immunodeficiency virus (HIV)1]. During the long-term treatment process, the appearance of drug resistance mutations to InSTIs is inevitable. A meta-analysis has shown that the resistance rate among InSTI treatment-experienced patients is 3.9％ (Raltegravir, RAL), 1.2％ (Elvitegravir, EVG), and 0.1％ (DTG)2]. However, resistance to InSTIs has not been reported in treatment-naive populations. |
| |
| Keywords: | |
| 本文献已被 万方数据 ScienceDirect 等数据库收录！ |
|
